Treece Medical Concepts (TMCI) Q3 2025: 11% Revenue Growth Masks Lapoplasty Weakness as Product Mix Shifts
Treece Medical Concepts delivered double-digit revenue growth in Q3 2025, but underlying softness in high-margin lapoplasty procedures and a shift toward lower-ASP minimally invasive systems signal a complex transition phase. Management revised full-year guidance downward, citing macro-driven elective procedure deferrals, a non-recurring distributor inventory build, and evolving surgeon preferences. The company’s broadened bunion solutions portfolio is gaining traction, but the path to sustainable top-line acceleration hinges on driving higher adoption of flagship systems and recapturing deferred procedures as sentiment improves.
Summary
- Product Mix Realignment: Lower-ASP minimally invasive systems are gaining share, pressuring top-line growth and margins.
- Elective Procedure Deferrals: Softer consumer sentiment and macro headwinds are driving a 7% decline in bunion surgeries year-to-date.
- 2026 Inflection Watch: Execution on innovation pipeline and sales force expansion will determine if TMCI can reignite lapoplasty adoption.
Performance Analysis
Treece Medical Concepts posted $50.2 million in Q3 revenue, up 11% year-over-year, with growth driven primarily by increased bunion procedure kit volumes and a significant contribution from stocking distributor sales. However, the quarter’s top-line momentum was partially inflated by approximately $6 million in distributor inventory build, half of which represented a pull-forward that will not recur in Q4, creating a near-term headwind.
Gross margin compressed slightly to 79.1%, reflecting a shift in product mix toward lower-ASP minimally invasive osteotomy systems and away from the company’s flagship lapoplasty line. Operating expenses rose 8% as TMCI invested in medical education, surgeon training, and incurred restructuring and litigation charges. While adjusted EBITDA loss narrowed by 49% year-over-year, net loss increased to $16.3 million, highlighting the lag between product portfolio expansion and sustainable profitability.
- Mix Shift Pressure: Growth in lower-priced new systems diluted revenue per procedure, offsetting case volume gains.
- Distributor Sales Timing: Q3 benefited from $3 million in non-recurring distributor stocking, setting up a Q4 revenue headwind.
- Expense Discipline: Cash burn improved 17% in Q3 and 58% year-to-date, with management signaling continued cost control efforts.
Year-to-date net loss improved versus 2024, but the company’s revised full-year outlook now calls for just 1% to 2% growth, underscoring the challenge of offsetting lapoplasty softness and external demand headwinds with new product adoption.
Executive Commentary
"We are not satisfied with our results and that we are not delivering the growth we'd initially planned for the year. However, looking ahead, we believe we are strongly positioned to drive market share gains with our new products innovation pipeline, and ability to leverage our dedicated commercial organization."
John Treece, Chief Executive Officer
"We had – reported somewhat of a restructuring charge already in Q3 where we've looked for opportunities to make some changes in the organization and the cost structure, and we'll continue to evaluate levers as we move forward. Fortunately for us, we have a very scalable business. We have high margins, and we're focused on driving the top line and improving profitability."
Mark Hare, Chief Financial Officer
Strategic Positioning
1. Portfolio Diversification and Market Coverage
TMCI has evolved from a single-technology provider to a comprehensive bunion solutions company, now offering five instrumented systems that address all four bunion deformity classes. The addition of three new minimally invasive systems in 2025 positions the company to capture a broader spectrum of surgeon preferences, particularly as the market shifts toward less invasive procedures.
2. Lapoplasty Under Pressure, New Systems Gain Traction
Lapoplasty, TMCI’s flagship high-ASP system, is losing share to minimally invasive osteotomies, which now represent the bulk of bunion procedures. While new system launches drove mid-single-digit case volume growth in Q3, the mix shift diluted revenue and margin. The company’s strategy is to use its expanded portfolio to pull surgeons into the lapoplasty ecosystem, but adoption rates from new product users have yet to offset the volume decline in the core segment.
3. Commercial Execution and Sales Force Expansion
TMCI invested in commercial leadership and expanded its sales team, bringing on a chief commercial officer, a new SVP of Sales, and additional foot and ankle specialists. Over 20% of existing surgeon customers adopted at least one new bunion technology in Q3, and management is emphasizing surgeon training events and pipeline innovation to drive further penetration and cross-sell opportunities.
4. Innovation Pipeline for 2026
Next-generation products, including the Lapoplasty Lightning platform and Percuplasty compression screw system, are expected to debut in 2026. These innovations target both procedural efficiency and expansion into adjacent foot and ankle reconstruction opportunities, aiming to reignite top-line growth and deepen customer engagement.
5. Cost Structure and Profitability Focus
Management is actively managing expenses, as seen in Q3 restructuring charges and a stated commitment to further cost controls. The business model remains scalable, and margin preservation is a key focus as the company navigates lower-ASP product adoption and macro-driven demand volatility.
Key Considerations
TMCI’s Q3 results reflect a business in strategic transition, balancing innovation-driven market expansion with the realities of shifting procedure mix and external headwinds. Investors must weigh the near-term revenue and margin pressure against the company’s efforts to reposition for long-term growth.
Key Considerations:
- Surgeon Preference Shift: Market momentum is favoring minimally invasive osteotomy over traditional lapoplasty, challenging the legacy revenue base.
- Deferred Elective Procedures: Broader macroeconomic weakness and consumer sentiment are causing a 7% decline in bunion surgeries year-to-date, with uncertain timing for recovery.
- Distributor Inventory Build: Q3’s $6 million in stocking distributor sales, half above plan, will not repeat, impacting Q4 comparability.
- Adoption Ramp of New Systems: Early traction is positive, but cross-sell to lapoplasty and full portfolio adoption are critical to restoring top-line momentum.
- Cost Control Levers: Ongoing restructuring and a focus on cash burn reduction are necessary to support profitability through the transition.
Risks
TMCI faces significant risk from continued softness in elective procedure volumes, persistent mix shift away from high-margin lapoplasty, and execution challenges in driving adoption of new systems. Macro uncertainty and consumer sentiment could further delay recovery, while competitive pressures in minimally invasive technologies may intensify. The company’s reliance on distributor inventory dynamics introduces added near-term volatility.
Forward Outlook
For Q4 2025, Treece Medical Concepts guided to:
- Revenue reflecting the absence of Q3 distributor stocking benefit, implying a sequential decline
- Continued case volume growth but lower ASP mix
For full-year 2025, management lowered guidance:
- Revenue of $211 million to $213 million, 1% to 2% growth over 2024
- Adjusted EBITDA loss of $6.5 million to $7.5 million, a 32% to 41% improvement
- Cash burn reduction of 43% to 47% versus 2024
Management highlighted several factors that will drive 2026 trajectory:
- Innovation pipeline launches and expanded sales force productivity
- Potential recovery in elective procedures if consumer sentiment improves
Takeaways
TMCI’s Q3 showcased the tension between innovation-led expansion and legacy product headwinds. The company is gaining share in minimally invasive bunion procedures, but the margin and revenue trade-off is material. Execution on cross-selling, cost discipline, and innovation launches will determine whether TMCI can return to robust, profitable growth in 2026.
- Mix Shift Headwind: Lower-ASP systems are growing, but not yet offsetting lapoplasty weakness, highlighting the challenge of sustaining revenue and margin expansion.
- Execution on New Product Adoption: Early signs are positive, but deeper penetration and pull-through to flagship systems are required for a full turnaround.
- 2026 Recovery Hinge: Investors should monitor elective procedure trends, innovation launches, and the effectiveness of the expanded sales force as leading indicators of inflection.
Conclusion
Treece Medical Concepts is navigating a pivotal transition as it broadens its bunion solutions portfolio and adapts to changing market dynamics. While Q3 delivered headline growth, underlying mix and macro headwinds temper the outlook. The company’s ability to drive adoption of both new and flagship systems, manage costs, and capture deferred demand will define its path forward.
Industry Read-Through
TMCI’s results underscore the accelerating shift within orthopedics toward minimally invasive procedures, with traditional high-ASP systems facing volume and margin erosion. Elective procedure deferrals, driven by consumer sentiment and macro factors, are a sector-wide challenge, impacting device makers reliant on discretionary surgeries. Competitive intensity in foot and ankle solutions is likely to increase as peers follow TMCI’s portfolio expansion playbook. For medtech investors, monitoring product mix, distributor inventory dynamics, and the timing of elective demand recovery remains critical across the industry.